WHY?
·
·Decreasing
size of the PP populations that may be distributed unequally
·
·Inaccurate assessment of the true efficacy for one or
both of the treatment arms
·
·Database
size insufficient to draw conclusions about a drugs efficacy in CSST infections or in the diabetic
foot subset